1. Home
  2. FOA vs GALT Comparison

FOA vs GALT Comparison

Compare FOA & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Finance of America Companies Inc.

FOA

Finance of America Companies Inc.

HOLD

Current Price

$19.15

Market Cap

183.8M

Sector

Finance

ML Signal

HOLD

Logo Galectin Therapeutics Inc.

GALT

Galectin Therapeutics Inc.

HOLD

Current Price

$3.03

Market Cap

176.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOA
GALT
Founded
2013
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
183.8M
176.7M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
FOA
GALT
Price
$19.15
$3.03
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$29.75
$8.50
AVG Volume (30 Days)
71.5K
231.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$29.44
N/A
Revenue Next Year
$14.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.58
$1.15
52 Week High
$29.58
$7.13

Technical Indicators

Market Signals
Indicator
FOA
GALT
Relative Strength Index (RSI) 30.81 48.30
Support Level N/A $2.90
Resistance Level $23.38 $3.24
Average True Range (ATR) 1.00 0.19
MACD -0.24 0.07
Stochastic Oscillator 19.05 62.86

Price Performance

Historical Comparison
FOA
GALT

About FOA Finance of America Companies Inc.

Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.

About GALT Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Share on Social Networks: